While both injectable Ozempic and oral Rybelsus contain semaglutide and have approval for type 2 diabetes, Novo Nordisk suggest the brand name Ozempic is more synonymous with GLP-1 medications, hence the rename
While this is a very large study, which followed patients for a long time, we cant yet know the potential impact of sustained use of medications like these, especially in cardiovascular patients who are not living with overweight and obesity
How semaglutide dosing works Semaglutide was the first GLP-1 receptor agonist to gain widespread attention for weight management
Reduced Risk of Obesity-Related Conditions: By facilitating weight loss, semaglutide can also reduce the risk of developing other obesity-related conditions, fatty liver disease, such as sleep apnea, and certain types of cancer
#GLP-1 #Obesity #Diabetes #Cardiovascular With an FDA label expansion, Novo Nordisk's Rybelsus becomes the first oral GLP-1 available to reduce the risk of major adverse cardiovascular events, including heart attack and stroke